

Disclosure statement: Wessex AHSN and Sanofi

Project title

Wessex AHSN Lipid Pathway Mapping Project

Organisations involved

Wessex Academic Health Science Network, Sanofi

Summary

The aim of Wessex AHSN working in partnership with Sanofi is to understand the different lipid pathways within the region, identifying the existing pressure points within services and whether inequity is contributing to overall health inequalities.

Background

Cardiovascular disease (CVD) affects around seven million people in the UK and is a significant cause of disability and death. The NHS Long Term Plan (LTP) (2019) includes an ambition to prevent 150,000 strokes, heart attacks and cases of dementia over the next ten years.

The LTP also includes reference to familial hypercholesterolemia (FH), an inherited condition which leads to raised cholesterol in about 250,000 people across the UK. Our ambition is to improve detection of FH from the current 4% to 15% of the prevalent population by 2023. The NHS Long Term Plan has also set the ambitious target of finding 25% of the predicted FH patients in England by 2029.

There is an urgent need to review, treat and optimise these patients in a timely manner. Clinical teams leading prevention in primary and secondary care have identified that the lipid services across the Wessex geography need to change to meet increasing demands and to ensure patients receive the best possible care with the best possible experience of the service.

Project approach

Project management input from Sanofi will support the NHS across Wessex to develop and approve a delivery plan to review the existing pathways and provision across the region, working closely with the Wessex AHSN CVD programme lead to identify areas for improvement in lipid services.

Project objectives

The mapping of the lipid service pathway will:

- gather evidence along the patient pathway to identify areas for improvement
- develop an options appraisal for new improved patient pathway throughout Wessex for patients with lipid disorders
- implement changes to the pathway agreed by the project group
- measure the effect of the implemented changes.

Benefits

The collaborative working project aims to deliver better understanding of services and how they are meeting the needs of the population, leading to service improvements allowing for more equitable, improved and quicker access to care for the patients across the AHSN footprint.

Funding dates

Funding was received for the period January 2023 to December 2023.

Funding details

There are no direct costs for this project. Indirect costs breakdown as follows:

Indirect staff costs incurred by Sanofi

Based on less than one day a week to provide project management support and support mapping of the pathway over a 6 month period of the project, this equates to a total of 136 hours.

Total indirect outlay by Sanofi during the project: £4,760

Indirect staff costs incurred by organisations receiving funding from NHS England

Total indirect outlay by NHS during the project £5088.71